Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.15 +0.10 (+0.42%)
Official Closing Price Updated: 7:00 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
From Arvinas Inc.
Via GlobeNewswire
2024 R&D Spending and Intensity Benchmarks
Via PRLog
Topics Supply Chain
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
From Pfizer Inc.
Via Business Wire
University of the People – an accredited, tuition free University announces record-breaking enrollment for 2025
Unprecedented Student Growth including thousands of refugees 
Via PRUnderground
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
From Olema Oncology
Via GlobeNewswire
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
From Pfizer Inc.
Via Business Wire
Medicus Pharma (NASDAQ:MDCX) Solution To Vaccine Cold Chain Storage Could Upend $40 Billion+ Market
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
Medicus Pharma (NASDAQ:MDCX) Solution To Vaccine Cold Chain Storage Could Upend $40 Billion+ Market
Via AB Newswire
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
Via AB Newswire
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
From Pfizer Inc.
Via Business Wire
Positive Gems Becomes the World’s Most Followed Modern Pharmaceutical Brand
Via Get News
Topics Intellectual Property
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance
From Pfizer Inc.
Via Business Wire
Michael McTague: How can anyone afford breakthrough medicines?
The cost of high-end, breakthrough medications traumatizes patients and their families. According to USAfacts, “national spending on personal health care has 
Via Equities.com
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Via Investor Brand Network
Topics Government
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
AtrendLtd Launches "Investing in Medical Innovation" Initiative to Accelerate Healthcare Transformation
August 1, 2025 -- Global investment firm AtrendLtd unveils new strategy focusing on five high-growth healthcare segments, aiming to support medical technology breakthroughs and generate sustainable... 
Via 24-7 Press Release
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Pfizer’s ‘Depo-Provera’ Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control Pill According to New Study as Litigation Overseen by Levin Papantonio Rises to Over 550 Lawsuits
From Levin Papantonio
Via GlobeNewswire
Pfizer Completes Licensing Agreement with 3SBio
From Pfizer Inc.
Via Business Wire
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
From Pfizer Inc.
Via Business Wire
Dynamic Global Events Presents: The 6th Clinical Trial Agreements Summit
Via Investor Brand Network
Topics Intellectual Property
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
From Pfizer Inc.
Via Business Wire
Pfizer Declares Third-Quarter 2025 Dividend
From Pfizer Inc.
Via Business Wire
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)
With clinical catalysts on the horizon and a seasoned biotech insider doubling down, Could Nuvectis Pharma (NASDAQ:NVCT)* Become the Next Summit Therapeutics (NASDAQ: SMMT)? 
Via News Direct
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.